Preclinical Models and Approaches for the Discovery of New Anticancer Therapies

TOPICAL COLLECTIONS

Guest Editor

Vish Muthusamy

Dept. of Internal Medicine (Medical Oncology and Hematology), Yale University

Vish Muthusamy is a Research Scientist in the Department of Internal Medicine and serves as the Director of the Precision Cancer Modeling Center at Yale. He is a cancer biologist with expertise in cancer genetics, epigenetics, immunobiology, and pharmacology.His research focuses on genetic alterations that drive cancer initiation and progression, and he has developed in vivo tumor models to better understand disease mechanisms. Dr. Muthusamy works closely with medicinal chemists to develop therapeutic agents targeting cancer, infectious pathogens, and immune disorders.Dr. Muthusamy’s current interests center on the discovery and pharmacological development of anticancer drugs, with particular emphasis on designing and conducting preclinical studies and advancing promising candidate therapies toward clinical application.

Collection Overview

Cancer incidence is rising worldwide, intensifying the demand for more effective therapies. Progress in drug discovery has been constrained by the complexity of cancer biology and the failure of existing preclinical models to faithfully represent human disease. To overcome these barriers, rigorous and predictive preclinical design approaches are required to demonstrate meaningful advantages over current standards of care.

This topical collection highlights innovative tumor models and preclinical strategies that accurately recapitulate human tumor biology and treatment response, providing a critical framework for the successful translation of next-generation anticancer therapies.